Screening for breast cancer

Stephen W Duffy; Robert A Smith; Rhian Gabe; László Tabár; Amy M F Yen; Tony H H Chen

doi:10.1016/j.soc.2005.06.001

Screening for breast cancer

Stephen W Duffy, Robert A Smith, Rhian Gabe, László Tabár, Amy M F Yen, Tony H H Chen

The Hull York Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

Strong evidence supports the value of breast cancer screening with mammography, and high-quality mammography screening can be considered a major public health achievement. As noted earlier in the discussion about the evaluation of service screening, the group of women who did not participate in mammographic screening in the decades after screening had been introduced had essentially unchanged or only minor improvements in mortality compared with the pattern before the introduction of screening, despite widespread use of adjuvant chemotherapy or hormonal therapy. Breast cancer should be treated in its preclinical phase if we are to save the lives of women with this disease, and a considerable body of evidence outlines best practices that, with broader adherence, would result in greater breast cancer mortality reductions than have been observed to date.

Original language	English
Pages (from-to)	671-97
Number of pages	27
Journal	Surgical oncology clinics of North America
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2005.06.001
Publication status	Published - 2005

Access to Document

10.1016/j.soc.2005.06.001

Cite this

@article{bbc8f8818de0440186d365c12af76815,

title = "Screening for breast cancer",

abstract = "Strong evidence supports the value of breast cancer screening with mammography, and high-quality mammography screening can be considered a major public health achievement. As noted earlier in the discussion about the evaluation of service screening, the group of women who did not participate in mammographic screening in the decades after screening had been introduced had essentially unchanged or only minor improvements in mortality compared with the pattern before the introduction of screening, despite widespread use of adjuvant chemotherapy or hormonal therapy. Breast cancer should be treated in its preclinical phase if we are to save the lives of women with this disease, and a considerable body of evidence outlines best practices that, with broader adherence, would result in greater breast cancer mortality reductions than have been observed to date.",

author = "Duffy, {Stephen W} and Smith, {Robert A} and Rhian Gabe and L{\'a}szl{\'o} Tab{\'a}r and Yen, {Amy M F} and Chen, {Tony H H}",

year = "2005",

doi = "10.1016/j.soc.2005.06.001",

language = "English",

volume = "14",

pages = "671--97",

journal = "Surgical oncology clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Screening for breast cancer

AU - Duffy, Stephen W

AU - Smith, Robert A

AU - Gabe, Rhian

AU - Tabár, László

AU - Yen, Amy M F

AU - Chen, Tony H H

PY - 2005

Y1 - 2005

N2 - Strong evidence supports the value of breast cancer screening with mammography, and high-quality mammography screening can be considered a major public health achievement. As noted earlier in the discussion about the evaluation of service screening, the group of women who did not participate in mammographic screening in the decades after screening had been introduced had essentially unchanged or only minor improvements in mortality compared with the pattern before the introduction of screening, despite widespread use of adjuvant chemotherapy or hormonal therapy. Breast cancer should be treated in its preclinical phase if we are to save the lives of women with this disease, and a considerable body of evidence outlines best practices that, with broader adherence, would result in greater breast cancer mortality reductions than have been observed to date.

AB - Strong evidence supports the value of breast cancer screening with mammography, and high-quality mammography screening can be considered a major public health achievement. As noted earlier in the discussion about the evaluation of service screening, the group of women who did not participate in mammographic screening in the decades after screening had been introduced had essentially unchanged or only minor improvements in mortality compared with the pattern before the introduction of screening, despite widespread use of adjuvant chemotherapy or hormonal therapy. Breast cancer should be treated in its preclinical phase if we are to save the lives of women with this disease, and a considerable body of evidence outlines best practices that, with broader adherence, would result in greater breast cancer mortality reductions than have been observed to date.

U2 - 10.1016/j.soc.2005.06.001

DO - 10.1016/j.soc.2005.06.001

M3 - Article

C2 - 16226686

SN - 1055-3207

VL - 14

SP - 671

EP - 697

JO - Surgical oncology clinics of North America

JF - Surgical oncology clinics of North America

IS - 4

ER -